意大利绩效风险分担协议实施经验及启示  

Implementation Experience and Reference of Performance-Based Risk-Sharing Arrangements in Italy

作　　者：徐伟[1] 马丽[1] 杨爽[1] 杜珍珍[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国卫生经济》2016年第11期94-96,共3页Chinese Health Economics

摘　　要：2006年意大利针对高值药品实施绩效风险分担协议,该政策的实施有效提高了重特大疾病患者的可负担性与药物可及性,同降低了政府财政负担。目前,我国正探索实施高值药品谈判政策,通过介绍意大利绩效风险分担协议的背景、主要内容、谈判流程以及政策,以期为我国高值药品谈判政策的实施提供参考。In 2006, Italy has implemented Good Practices for Performance-Based Risk-Sharing Anangements（PBRSAs） for high value drugs for critical illnesses. The implementation of policy effectively increased the affordability and availability of drugs for critical illness and reduced the financial burden of government. In current, China is exploring the negotiation policy of high value drugs tor critical illnesses. The background, main content, negotiation process and policy of Italy＇ s PBRSAs were introduced to provide references for the implementation of China＇s PBRSAs.

关 键 词：高值药品 绩效风险分担协议 意大利 

分 类 号：R197.1[医药卫生—卫生事业管理]